This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Mablife, National Institute of Health and Medical Research. Active years: 2015-2019.
Location History:
- Toulouse Cedex, FR (2015)
- Toulouse, FR (2019)
Company Filing History:
2 out of 3 
2 out of 1,853 
Years Active: 2015-2019
Title: Philippe Le Bouteiller: Innovator in Eye Disorder Treatments
Introduction
Philippe Le Bouteiller is a notable inventor based in Toulouse, France. He has made significant contributions to the field of medical research, particularly in the treatment of eye disorders. With a total of 2 patents, his work focuses on innovative therapeutic approaches.
Latest Patents
Le Bouteiller's latest patents include the development of anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis. This invention relates to the use of at least one anti-CD160 antibody, preferably a compound selected from the CL1-R2 monoclonal antibody, which may be obtained by the hybridoma CNCM 1-3204. The invention aims to prepare a drug designed to treat neovascular eye diseases.
Career Highlights
Throughout his career, Philippe Le Bouteiller has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Mablife. His research has contributed to advancements in medical treatments and has garnered attention in the scientific community.
Collaborations
Le Bouteiller has collaborated with notable professionals in his field, including Armand Bensussan. These partnerships have enhanced the impact of his research and innovations.
Conclusion
Philippe Le Bouteiller's work in developing anti-CD160 specific antibodies represents a significant advancement in the treatment of eye disorders. His contributions continue to influence the medical field and offer hope for patients suffering from neovascular eye diseases.